Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTPA Chelation for Gadolinium Deposition Disease
NCT05359835Phase 1Withdrawn
- Sponsor
- Stanford University
- Start
- Apr 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pentetate calcium trisodium and zinc diethylenetriaminepentaacetic acid in Gadolinium deposition disease (GDD), sponsored by Stanford University. Primary endpoint: 0-10 Scale of Pain Severity. Planned start Apr 2023; status: withdrawn.
02
Drugs
pentetate calcium trisodiumzinc diethylenetriaminepentaacetic acid
03
Conditions
Gadolinium deposition disease (GDD)
Beyond the preview
Go deeper on NCT05359835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05359835.